Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

NCT03006770 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

213

Enrollment

INDUSTRY

Sponsor class

Conditions

Critical Limb Ischemia (CLI)

Interventions

BIOLOGICAL: PLX-PAD
BIOLOGICAL: Placebo

Sponsor

Pluristem Ltd.